Corvus Pharmaceuticals, Inc. (CRVS) SEC Filings & Earnings Calls

Clinical-stage biotech with no approved products; depends on trial success.

“Clinical-stage biopharmaceutical company... soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track”

Clinical trial failure risk

“Our product candidates are in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability.” · word for word

Need for additional capital

“We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.” · word for word

No revenue from product sales

“We are a clinical-stage biopharmaceutical company that has never generated revenue from the sale of our product candidates.” · word for word

Board departure may signal governance concerns if pattern emerges, but isolated resignation is routine.

“Single director resignation after long tenure; no stated reason.”

Early-stage clinical data; further trials needed for regulatory approval.

“Phase 1 trial; no Phase 2 or Phase 3 data yet.”

No approved products or revenue

“To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from sales of commercial products.” · word for word

Need for additional capital

“To fund all of the Company's ongoing and planned development programs through commercialization, the Company will need to raise additional capital in the future.” · word for word

Clinical trial and regulatory uncertainty

“Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, the Company may not be able to accurately estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of soquelitinib, or any other product candidates.” · word for word

No approved products; clinical-stage risk; net loss and no revenue

“Clinical-stage biopharmaceutical company; net loss $13.7M; no revenue reported.”

Resignation of long-serving director and audit committee chair may signal governance transition, but no immediate risk.

“Scott Morrison delivered notice of his intention to resign from the Board effective as of April 23, 2026” · word for word

Potential shareholder dilution from future ATM sales; no shares sold under prior agreement suggests cautious execution.

“Maximum offering price doubled to $200M; no prior sales under original agreement.”

Clinical trial failure risk

“Our product candidates are in various stages of development and may fail or suffer delays that materially and adversely affect their commercial viability.” · word for word

Financing risk

“We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.” · word for word

Competition risk

“We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.” · word for word

Clinical trial risk: Phase 2 atopic dermatitis and Phase 3 PTCL trials may not replicate Phase 1 results.

“Phase 2 atopic dermatitis trial enrolling ~200 patients; Phase 3 PTCL enrolling 150 patients.”

Dilution risk from recent $189M offering; potential future ATM sales.

“Completed public offering; ATM facility increased to $200M.”

Dilution risk from issuance of ~9.09M new shares, representing significant ownership dilution for existing shareholders.

“Issuance of 7,900,677 shares plus 1,185,101 option shares.”

Suspension of ATM offering may signal difficulty in raising capital under current market conditions or strategic shift.

“Company suspended offering of shares under ATM program; no shares had been sold.”

Clinical trial risk remains; Phase 2 trial planned but results are preliminary and based on small sample size.

“Phase 1 data from cohort 4 with 12 soquelitinib patients; Phase 2 trial planned but not yet initiated.”

Going concern / capital insufficiency

“Given our planned expenditures for the next year and our cash, cash equivalents and marketable securities of $65.7 million as of September 30, 2025, we do not expect that our existing capital resources will be sufficient to fund our operations through a period of at least 12 months from beyond the filing of this Quarterly Report on Form 10-Q.” · word for word

Clinical trial failure risk

“Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies and early clinical trials are not necessarily predictive of future results.” · word for word

Regulatory approval risk

“Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.” · word for word